Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Assets Average: 2019-2025

Historic Assets Average for BridgeBio Pharma (BBIO) over the last 6 years, with Sep 2025 value amounting to $1.0 billion.

  • BridgeBio Pharma's Assets Average rose 42.42% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 42.42%. This contributed to the annual value of $732.9 million for FY2024, which is 25.34% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Assets Average of $1.0 billion as of Q3 2025, which was up 5.94% from $980.9 million recorded in Q2 2025.
  • BridgeBio Pharma's Assets Average's 5-year high stood at $1.1 billion during Q2 2021, with a 5-year trough of $564.7 million in Q2 2023.
  • Over the past 3 years, BridgeBio Pharma's median Assets Average value was $729.7 million (recorded in 2024), while the average stood at $757.4 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Assets Average slumped by 32.59% in 2023, and later surged by 45.55% in 2024.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Assets Average stood at $897.2 million in 2021, then dropped by 24.66% to $675.9 million in 2022, then fell by 11.13% to $600.7 million in 2023, then surged by 31.87% to $792.2 million in 2024, then surged by 42.42% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q3 2025, $980.9 million for Q2 2025, and $900.5 million during Q1 2025.